APPLICATION
NDA017422
TYPE
NDA
ORIGINAL APPROVAL
1977-03-07
LATEST ACTION
2021-04-30
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
BICNU · ReferencePrescription
CARMUSTINE 100MG/VIAL · INJECTABLE · INJECTION
Approval history
2015-11-25Manufacturing (CMC) · Supplement 49 · standardAP
1997-09-10Labeling · Supplement 34 · standardAP
1992-12-11Labeling · Supplement 31AP
1992-07-13Manufacturing (CMC) · Supplement 32 · standardAP
1991-06-13Manufacturing (CMC) · Supplement 29 · standardAP
1991-01-03Manufacturing (CMC) · Supplement 28 · standardAP
1989-09-14Manufacturing (CMC) · Supplement 27 · standardAP
1989-04-19Manufacturing (CMC) · Supplement 25 · standardAP
1988-05-17Manufacturing (CMC) · Supplement 24 · standardAP
1988-01-12Manufacturing (CMC) · Supplement 23 · standardAP
1987-10-26Labeling · Supplement 22AP
1987-08-07Manufacturing (CMC) · Supplement 20 · standardAP
1987-04-21Labeling · Supplement 8AP
1987-03-05Manufacturing (CMC) · Supplement 19 · standardAP
1986-07-11Labeling · Supplement 15AP
1986-05-19Labeling · Supplement 17AP
1986-05-19Labeling · Supplement 18AP
1986-05-19Labeling · Supplement 16AP
1984-12-10Manufacturing (CMC) · Supplement 14 · standardAP
1984-08-08Manufacturing (CMC) · Supplement 13 · standardAP
1984-04-03Manufacturing (CMC) · Supplement 6 · standardAP
1984-03-13Manufacturing (CMC) · Supplement 12 · standardAP
1984-02-17Manufacturing (CMC) · Supplement 10 · standardAP
1983-06-29Labeling · Supplement 11AP
1983-02-10Manufacturing (CMC) · Supplement 9 · standardAP
1982-02-16Labeling · Supplement 7AP
1980-11-12Labeling · Supplement 5AP
1979-10-09Manufacturing (CMC) · Supplement 3 · standardAP
1979-10-09Labeling · Supplement 4AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.